Literature DB >> 3160724

Management of dislocation of the hip in Down syndrome.

H Aprin, W P Zink, J E Hall.   

Abstract

Six patients with Down syndrome were treated for dislocation of the hip (10 hips). Follow-up averaged 49 months. Group I consisted of three patients (six hips) with dislocatable hips and normal acetabula treated with capsular plication and/or proximal femoral osteotomy. Group II consisted of three patients (four hips) with dislocatable hips and dysplastic and insufficient acetabula treated with capsular plication, Salter osteotomy, and proximal femoral osteotomy. Results were rated as satisfactory in four patients (seven hips) and unsatisfactory in two patients (three hips).

Entities:  

Mesh:

Year:  1985        PMID: 3160724     DOI: 10.1097/01241398-198507000-00007

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  4 in total

1.  Effect of the Sharrard procedure on hip instability in children with Down syndrome: a retrospective study.

Authors:  Frederike E C M Mulder; Levinus A Bok; Florens Q M P van Douveren; Hans E H Pruijs; Adelgunde V C M Zeegers
Journal:  J Child Orthop       Date:  2021-10-01       Impact factor: 1.548

2.  Preliminary results of an anteverting triple periacetabular osteotomy for the treatment of hip instability in Down syndrome.

Authors:  D A Maranho; Y-J Kim; K A Williams; E N Novais
Journal:  J Child Orthop       Date:  2018-02-01       Impact factor: 1.548

3.  Femoral and Dega osteotomies in the treatment of habitual hip dislocation in Down syndrome patients - is it efficient or not?

Authors:  Ahmad S Aly; Mohamed A Al-Kersh
Journal:  J Child Orthop       Date:  2018-06-01       Impact factor: 1.548

4.  Management of recurrent hip dislocation in Down Syndrome using modified Ganz periacetabular osteotomy: Follow up after 5 years.

Authors:  Ismail Hadisoebroto Dilogo; Jessica Fiolin; Juniarto Jaya Pangestu; Amri Muhyi
Journal:  Ann Med Surg (Lond)       Date:  2020-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.